Immune Monitoring in Melanoma and Urothelial Cancer Patients Treated with Anti-PD-1 Immunotherapy and SBRT Discloses Tumor Specific Immune Signatures

SIMPLE SUMMARY: Currently available biomarkers for response to checkpoint inhibitors are incomplete and predominantly focus on tumor tissue analysis e.g., tumor mutational burden, programmed cell death-ligand 1 (PD-L1) expression. Biomarkers in peripheral blood would allow a more dynamic monitoring...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancers (Basel)
Main Authors: Meireson, Annabel, Tavernier, Simon J., Van Gassen, Sofie, Sundahl, Nora, Demeyer, Annelies, Spaas, Mathieu, Kruse, Vibeke, Ferdinande, Liesbeth, Van Dorpe, Jo, Hennart, Benjamin, Allorge, Delphine, Haerynck, Filomeen, Decaestecker, Karel, Rottey, Sylvie, Saeys, Yvan, Ost, Piet, Brochez, Lieve
Format: Artigo
Jezik:Inglês
Izdano: MDPI 2021
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8198315/
https://ncbi.nlm.nih.gov/pubmed/34071888
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13112630
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki